Inhibikase Therapeutics Ownership | Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics Ownership Summary

Inhibikase Therapeutics is owned by 107.55% institutional investors, 6.42% insiders. Sands capital ventures is the largest institutional shareholder, holding 13.24% of IKT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.59% of its assets in Inhibikase Therapeutics shares.

IKT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Inhibikase Therapeutics	107.55%	6.42%	-13.97%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Sands capital ventures	13.02M	13.24%	$21.87M
Soleus capital management	10.88M	11.06%	$18.27M
Fairmount funds management	8.63M	8.77%	$14.49M
Blackrock funding, inc. /de	6.30M	6.41%	$10.59M
Blackstone	5.94M	6.04%	$9.98M
Siren	5.85M	5.95%	$9.83M
Adar1 capital management	5.25M	5.83%	$8.50M
Commodore capital lp	5.40M	5.49%	$9.07M
Vanguard group	4.56M	5.06%	$9.35M
Saturn v capital management	3.86M	3.93%	$6.49M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sands capital ventures	13.02M	5.19%	$21.87M
Caxton	28.45K	1.19%	$47.80K
Saturn v capital management	3.86M	1.18%	$6.49M
Fairmount funds management	8.63M	1.05%	$14.49M
Adar1 capital management	5.25M	0.80%	$8.50M
Soleus capital management	10.88M	0.74%	$18.27M
Stonepine capital management	957.20K	0.64%	$1.61M
Commodore capital lp	5.40M	0.52%	$9.07M
Rangeley capital	220.00K	0.36%	$369.60K
Siren	5.85M	0.27%	$9.83M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock funding, inc. /de	6.30M	0.00%	3.00M
Millennium management	2.93M	0.00%	2.76M
Summittx capital	1.52M	0.08%	1.52M
Vanguard group	4.56M	0.00%	1.29M
State street	1.69M	0.00%	1.13M

Top Sellers

Holder	Shares	% Assets	Change
Perceptive advisors	2.31M	0.08%	-3.11M
Stonepine capital management	957.20K	0.64%	-1.39M
Ameriprise financial	-	-	-1.38M
Nantahala capital management	2.70M	0.17%	-1.23M
Exome asset management	-	-	-600.00K

New Positions

Holder	Shares	% Assets	Change	Value
Summittx capital	1.52M	0.08%	1.52M	$2.56M
Two sigma investments, lp	847.61K	0.00%	847.61K	$1.42M
Vanguard fiduciary trust	567.00K	0.00%	567.00K	$952.56K
Rangeley capital	220.00K	0.36%	220.00K	$369.60K
Aqr capital management	172.01K	0.00%	172.01K	$288.98K

Sold Out

Holder	Change
Raymond james financial	-1.00K
Amalgamated bank	-1.90K
Point72 (difc)	-1.98K
Cubist systematic strategies	-9.04K
Brevan howard capital management lp	-10.38K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	98	34.25%	105,732,105	-0.64%	107	0.77%	72	53.19%	13	-13.33%
Dec 31, 2025	7	-86.79%	4,678,736	-91.49%	5	0.14%	5	-78.26%	2	-86.67%
Sep 30, 2025	12	-75.00%	3,752,410	-93.12%	4	0.11%	4	-88.57%	5	-16.67%
Jun 30, 2025	48	6.67%	54,512,380	20.28%	60	2.38%	37	19.35%	6	100.00%
Mar 31, 2025	47	51.61%	51,462,756	2.80%	57	0.13%	31	3.33%	3	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	3.43M	2.59%	-
iShares Russell 2000 ETF	2.34M	1.77%	19.74K
Vanguard Institutional Extnd Mkt Idx Tr	909.24K	0.69%	-
iShares Russell 2000 Value ETF	815.98K	0.62%	4.40K
Fidelity Small Cap Index	591.63K	0.45%	3.98K
Vanguard Russell 2000 ETF	540.94K	0.41%	11.20K
Fidelity Extended Market Index	429.45K	0.33%	238.80K
State St Russell Sm/Mid Cp® Indx SL Cl I	428.50K	0.32%	-
State St Russell Sm Cap® Idx SL Cl I	403.40K	0.31%	-29.60K
State St Russell Sm Cap® Indx SL Cl I	403.40K	0.31%	-29.60K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 21, 2025	Sands Capital Life Sciences Pulse Fund II, L.P.	-	Buy	$3.00M
Oct 21, 2024	Bellini Roberto	-	Buy	$2.00M
Oct 21, 2024	Kush Arvind	-	Buy	$198.65K
Oct 21, 2024	Munshi Amit	-	Buy	$500.05K
Aug 16, 2022	Werner Milton H.	President and CEO	Buy	$4.00K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	1	-
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	3	-

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics shareholders are primarily institutional investors at 107.55%, followed by 6.42% insiders and -13.97% retail investors. The average institutional ownership in Inhibikase Therapeutics's industry, Biotech Stocks , is 35.75%, which Inhibikase Therapeutics exceeds.

Who owns the most shares of Inhibikase Therapeutics?

Inhibikase Therapeutics’s largest shareholders are Sands capital ventures (13.02M shares, 13.24%), Soleus capital management (10.88M shares, 11.06%), and Fairmount funds management (8.62M shares, 8.77%). Together, they hold 33.08% of Inhibikase Therapeutics’s total shares outstanding.

Does Blackrock own Inhibikase Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Inhibikase Therapeutics.

Who is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested?

Sands capital ventures is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.19% of its assets in 13.02M Inhibikase Therapeutics shares, valued at 21.87M$.

Who is the top mutual fund holder of Inhibikase Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Inhibikase Therapeutics shares, with 2.59% of its total shares outstanding invested in 3.43M Inhibikase Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools